Media Centre
Latest press releases
-
Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
-
Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
-
Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
-
Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
-
Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director, Global Media Relations (Corporate)
+44 (0)1223 344 800
Angela Fiorin
Director, Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Chris Calland
Director, Global Media Relations (Oncology)
+44 (0)1223 344 800
Fiona Cookson
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Sinead Keller
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
Holly Campbell
Head, US Corporate Affairs
+1 302 885 2677
Lisa Taylor
Senior Director, Corporate Communications (Alexion)
+1 857 338 9025
Amanda Talamonte
Manager, Global Media Relations
+44 (0)1223 344 800
Flavia Garcia
Manager, Global Media Relations
+44 (0)1223 344 800
